BRIEF published on 08/26/2026 at 17:50, 17 days 17 hours ago Mauna Kea Technologies : avancées dans le diagnostic des cancers digestifs Mauna Kea Technologies Endomicroscopie Méta-analyse Cancers Digestifs NECA
BRIEF published on 08/26/2026 at 17:50, 17 days 17 hours ago Mauna Kea Technologies Highlights Meta-Analysis on Cellvizio's Clinical Impact Mauna Kea Technologies Cellvizio Meta-analysis Upper Gastrointestinal Cancer PCLE
BRIEF published on 08/26/2026 at 17:50, 17 days 17 hours ago Mauna Kea Technologies met en lumière une méta-analyse sur l'impact clinique de Cellvizio Mauna Kea Technologies Cellvizio Méta-analyse PCLE Cancer De La Partie Supérieure Du Tube Digestif
BRIEF published on 08/26/2026 at 17:50, 17 days 17 hours ago Mauna Kea Technologies: Advances in the diagnosis of digestive cancers Mauna Kea Technologies Endomicroscopy Meta-analysis NECA Digestive Cancers
PRESS RELEASE published on 08/26/2026 at 17:45, 17 days 17 hours ago Inside Information / Other news releases Mauna Kea Technologies announces publication of a landmark systematic review and meta-analysis reinforcing the diagnostic accuracy and clinical impact of Cellvizio in upper gastrointestinal cancer Mauna Kea Technologies Cellvizio Meta-analysis Upper Gastrointestinal Cancer Systematic Review
PRESS RELEASE published on 08/26/2026 at 17:45, 17 days 17 hours ago Informations privilégiées / Autres communiqués Mauna Kea Technologies annonce une méta-analyse renforçant le diagnostic et l'impact clinique de Cellvizio dans les cancers digestifs hauts Mauna Kea Technologies Cellvizio Endomicroscopie Méta-analyse Cancers Digestifs
BRIEF published on 08/07/2026 at 17:50, 1 month 5 days ago Mauna Kea Technologies publie des informations sur les droits de vote et le capital social. Capital Social Droit De Vote Euronext Croissance Mauna Kea Technologies Règlementation De L'AMF
BRIEF published on 08/07/2026 at 17:50, 1 month 5 days ago Mauna Kea Technologies: Voting rights and share capital as of July 31, 2026 Share Capital Voting Rights AMF Euronext Growth Mauna Kea Technologies
BRIEF published on 08/07/2026 at 17:50, 1 month 5 days ago Mauna Kea Technologies Reports Voting Rights and Share Capital Details Share Capital Voting Rights Euronext Growth AMF Regulations Mauna Kea Technologies
BRIEF published on 08/07/2026 at 17:50, 1 month 5 days ago Mauna Kea Technologies : Droits de vote et capital au 31 juillet 2026 Droits De Vote Capital Social AMF Euronext Growth Mauna Kea Technologies
Published on 09/12/2026 at 02:35, 1 day 9 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 12 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 14 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 18 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 17 hours 47 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 4 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 13 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 13 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 15 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 4 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 4 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 16 hours ago Availability of the 2026 Interim Financial Report
